Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
“Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity”
February 28, 2019
Center for Biotechnology Director Dr. Clinton Rubin has co-authored a recent article published in Nature Reviews Endocrinology ““Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity”. Abstract below, full article here.
Abstract:
Osteoporosis, a condition of skeletal decline that undermines quality of life, is treated with pharmacological interventions that are associated with poor adherence and adverse effects. Complicating efforts to improve clinical outcomes, the incidence of obesity is increasing, predisposing the population to a range of musculoskeletal complications and metabolic disorders. Pharmacological management of obesity has yet to deliver notable reductions in weight and debilitating complications are rarely avoided. By contrast, exercise shows promise as a non-invasive and non-pharmacological method of regulating both osteoporosis and obesity. The principal components of exercise — mechanical signals — promote bone and muscle anabolism while limiting formation and expansion of fat mass. Mechanical regulation of bone and marrow fat might be achieved by regulating functions of differentiated cells in the skeletal tissue while biasing lineage selection of their common progenitors — mesenchymal stem cells. An inverse relationship between adipocyte versus osteoblast fate selection from stem cells is implicated in clinical conditions such as childhood obesity and increased marrow adiposity in type 2 diabetes mellitus, as well as contributing to skeletal frailty. Understanding how exercise-induced mechanical signals can be used to improve bone quality while decreasing fat mass and metabolic dysfunction should lead to new strategies to treat chronic diseases such as osteoporosis and obesity.
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
[post_title] => BioREACH: Translational Research Funding Opportunity
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bioreach-translational-research-funding-opportunity
[to_ping] =>
[pinged] =>
[post_modified] => 2026-09-04 11:55:36
[post_modified_gmt] => 2026-09-04 15:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5065
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3055
[post_author] => 3
[post_date] => 2018-09-04 13:33:40
[post_date_gmt] => 2018-09-04 13:33:40
[post_content] => Cold Spring Harbor Laboratory’s Alex Vaughan was awarded the 2018 Alexandria LaunchLabs Seed Capital Prize for the CSHL spinoff company MapNeuro Inc. during the NYC Life Science Innovation Showcase, held in New York City on June 14, 2018. Valued at $100,000, the prize, meant to fund early-stage development companies, includes a scholarship to Alexandria LaunchLabs, a cash award, and an investment from the Alexandria Seed Capital Platform, an innovative funding model catalyzing seed-stage life science investment.
MapNeuro Inc. commercializes “molecular connectomics” technology developed in the laboratory of CSHL Professor Anthony Zador. MapNeuro uses this platform to understand brain-wide patterns of neuronal connectivity, and is specifically targeting neurodegenerative diseases such as Parkinson’s Disease and Alzheimer’s Disease.
Read the full article here.
[post_title] => LIBH Innovator Awarded Alexandria LaunchLabs Seed Capital Prize
[post_excerpt] => CSHL spin-out MapNeuro Inc. was awarded the 2018 Alexandria LaunchLabs Seed Capital Prize during the NYC Life Science Innovation Showcase in June 2018.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => libh-innovator-awarded-alexandria-launchlabs-seed-capital-prize
[to_ping] =>
[pinged] =>
[post_modified] => 2018-09-04 13:46:01
[post_modified_gmt] => 2018-09-04 13:46:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=3055
[menu_order] => 112
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 1455
[post_author] => 3
[post_date] => 2015-03-16 19:45:43
[post_date_gmt] => 2015-03-16 19:45:43
[post_content] => Traverse Biosciences, founded by Joseph Scaduto - one of the Center for Biotechnology's first BioEntrepreneurs-in-Residence, announced today that it has executed an exclusive, worldwide license agreement with the Research Foundation for the State University of New York (RF/SUNY) for access to the animal health applications of a proprietary library of polyenolic zinc-binding agents. The license agreement also extends Traverse Biosciences the exclusive option to license the human health applications of these promising drug candidates.
The drug compounds were invented by Lorne Golub, DMD, MD (Honorary), Distinguished Professor in the Department of Oral Biology and Pathology in the Stony Brook University School of Dental Medicine, and Francis Johnson, PhD, President of Chem-Master International Inc. and Professor of Chemistry and Pharmacology at Stony Brook. The drugs were developed in concert with the the Center for Biotechnology at Stony Brook University. The Center provided financial support to help the inventors develop their lead compound and for follow-on animal studies.
Click to read the press releases from Stony Brook University and Traverse Biosciences.
[post_title] => Traverse Biosciences Executes Exclusive, Worldwide License Agreement
[post_excerpt] => Traverse Biosciences, founded by Joseph Scaduto - one of the Center for Biotechnology's first BioEntrepreneurs-in-Residence, has executed an exclusive, worldwide license agreement with the Research Foundation for the State University of New York (RF/SUNY).
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => traverse-biosciences-executes-exclusive-worldwide-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2015-03-16 19:46:46
[post_modified_gmt] => 2015-03-16 19:46:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1455
[menu_order] => 209
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4373
[post_author] => 4
[post_date] => 2024-02-08 15:17:50
[post_date_gmt] => 2024-02-08 20:17:50
[post_content] =>
Save the date to join us in New York City for the expanded, two-day Life Sciences Summit™ 2024! Visit lifesciencessummit.org for program & registration updates.
[post_title] => Save the Date! LSS 2024: October 8-9th!
[post_excerpt] => Save the date to join us in New York City for the expanded, two-day Life Sciences Summit™ 2024!
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => save-the-date-lss-2024-october-9th
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:48:53
[post_modified_gmt] => 2024-11-19 15:48:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4373
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
